

DAFTAR PUSTAKA

- Aravalli, R. N., Cressman, E. N. K. and Steer, C. J. (2013) 'Cellular and molecular mechanisms of hepatocellular carcinoma: An update', *Archives of Toxicology*, 87(2), pp. 227–247. doi: 10.1007/s00204-012-0931-2.
- Aravalli, R. N. and Steer, C. J. (2014) *Hepatocellular Carcinoma: Cellular and Molecular Mechanisms and Novel Therapeutic Strategies*.
- Balogh, J. *et al.* (2016) 'Hepatocellular carcinoma : a review', pp. 41–53. doi: <https://doi.org/10.2147/JHC.S61146>.
- Carr, B. I. (2016) *Hepatocellular Carcinoma Associated with Hepatitis B Virus, Hepatocellular Carcinoma Diagnosis and Treatment*. doi: DOI 10.1007/978-3-319-34214-6.
- Christos Georgiades and Jean-Francois Geschwind (2010) *Hepatocellular Carcinoma*. Edited by K. M. McMasters and J.-N. Vauthey. Springer.
- El-Serag, H. B. and Rudolph, K. L. (2007) 'Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis', *Gastroenterology*, 132(7), pp. 2557–2576. doi: 10.1053/j.gastro.2007.04.061.
- Kawaoka, T. *et al.* (2012) 'Evaluation of the mRECIST and α -fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib', *Oncology (Switzerland)*, 83(4), pp. 192–200. doi: 10.1159/000341347.
- Lai, Q. *et al.* (2012) 'Alpha-Fetoprotein and Novel Tumor Biomarkers as Predictors of Hepatocellular Carcinoma Recurrence after Surgery: A Brilliant Star Raises Again', *International Journal of Hepatology*, 2012, pp. 1–9. doi: 10.1155/2012/893103.

Lee, Y. K. *et al.* (2013) 'Prognostic value of α -fetoprotein and des- γ -carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization', *BMC Cancer*, 13. doi: 10.1186/1471-2407-13-5.

Lencioni, R. and Llovet, J. M. (2010) 'Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma', *Seminars in Liver Disease*, 30(212), pp. 52–60. doi: 10.1055/s-0030-1247132.

McEvoy, S. H. *et al.* (2013) 'Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Diseases', *RadioGraphics*, 33(6), pp. 1653–1668. doi: 10.1148/rg.336125104.

Mustaine, E. E., Higgins, G. E. and Tewksbury, R. (2012) 'EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma', *Journal of Applied Measurement*. European Association for the Study of the Liver, 9(1), pp. 36–44. doi: 10.1016/j.jhep.2011.12.001.

Oehadian, A. *et al.* (2013) 'The role of neutrophyl lymphocyte count ratio as an inflammatory marker in systemic lupus erythematosus.', *Acta medica Indonesiana*, 45(3), pp. 170–4.

Park, J.-W. *et al.* (2014) 'Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma', *Liver Cancer*, 3(3–4), pp. 439–450. doi: 10.1159/000343872.

Paul and Sharma (2014) 'Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma', *Journal of Clinical and Experimental Hepatology*. Elsevier Ltd, 4, pp. S112–S121. doi: 10.1016/j.jceh.2014.03.048.

- Paul, S. B. and Sharma, H. (2014) 'Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma', *Journal of Clinical and Experimental Hepatology*. Elsevier Ltd, 4(August), pp. S112–S121. doi: 10.1016/j.jceh.2014.03.048.
- Sanyal, A. J., Yoon, S. K. and Lencioni, R. (2010) 'The Etiology of Hepatocellular Carcinoma and Consequences for Treatment', *The Oncologist*, 15(Supplement 4), pp. 14–22. doi: 10.1634/theoncologist.2010-S4-14.
- Shukui Qin (2012) 'Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition)', *Chinese Clinical Oncology*, 1(1), pp. 1–32. doi: 10.3978/j.issn.2304-3865.2012.07.01.
- Stokes, T. L. (2006) *HEPATOCELLULAR CARCINOMA Diagnosis and Treatment Second Edition*, John Wiley & Sons, Inc. doi: 10.1037/023990.
- Thorn, C. F. *et al.* (2011) 'Doxorubicin pathways: Pharmacodynamics and adverse effects', *Pharmacogenetics and Genomics*, 21(7), pp. 440–446. doi: 10.1097/FPC.0b013e32833ffb56.
- Torzilli, G. *et al.* (2008) 'Hepatectomy for Stage B and Stage C Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer Classification', *Endoscopy*, 143(11), pp. 1082–1090.
- Veltri, A. *et al.* (2006) 'Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC)', *European Radiology*, 16(3), pp. 661–669. doi: 10.1007/s00330-005-0029-9.
- Verslype, C., Rosmorduc, O. and Rougier, P. (2012) 'Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment

and follow-up', *Annals of Oncology*, 23(SUPPL. 7). doi:
10.1093/annonc/mds225.

Wang, X. and Wang, Q. (2018) 'Alpha-fetoprotein and hepatocellular carcinoma immunity', *Canadian Journal of Gastroenterology and Hepatology*, 2018. doi: 10.1155/2018/9049252.